Yaolun Yang

Yaolun Yang

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2025 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
SLShu-Ning Liu
Shu-Ning Liu
Ching-Shiang ChiChing-Shiang Chi
Ching-Shiang Chi
HLHsiu-Fen Lee.
Hsiu-Fen Lee.
CTChi-Ren Tsai
Chi-Ren Tsai
Yaolun YangYaolun Yang
Yaolun Yang
PWPei Yu Wu
Pei Yu Wu
Background: The focus of this study was a comparison of the phenotypical and genotypical differences in PURA syndrome among Asian and non-Asian patients. A retrospective cohort study was performed in a single medical center from January 2014 to May 2025 on patients carrying causative genes for PURA syndrome. A systematic search in PubMed, MEDLINE, Web of Science, and Embase covering the period from January 2014 to May 2025 was conducted. Individuals with PURA syndrome were collected and categorized into Asian and non-Asian groups for analysis. Clinical characteristics, imaging findings, and developmental outcomes were compared between the two groups using Chi-squared or Fisher’s exact tests, with a p < 0.05 considered statistically significant. Results: Of 200 individuals enrolled, 44 were Asian and 156 were non-Asian. 80% or more of individuals with PURA syndrome in both groups shared common clinical features of hypotonia and feeding difficulties during the neonatal period. In terms of neurologic symptoms, there were significantly higher rates of pathological startle response (p < 0.01), and lower rates of epilepsy (p < 0.01) and movement disorders (p = 0.035) among Asian populations. For extra-neurologic symptoms, Asian populations showed a higher incidence of cardiac (p = 0.013) and urogenital abnormalities (p < 0.01), with statistical significance. A single patient in the cohort study exhibited second-degree atrioventricular block, which required pacemaker placement. Highly heterogeneous variants were identified with 106 causative variants in 200 individuals, including a novel causative variant, c.42_57del (p.Leu15fs), from our cohort. All individuals with PURA syndrome displayed evident psychomotor impairment during follow-up. Conclusions: PURA syndrome exhibits high phenotypic and genotypic heterogeneity. Increased pathological startle response, reduced epilepsy and movement disorders, and higher rates of cardiac and urogenital abnormalities were observed in the Asian group. Cardiac conduction disorder may prove fatal without timely intervention.

18 January 2023 in Children
Verified
Journal Article
Open access
PDF file
PWPei Yu Wu
Pei Yu Wu
Ching-Shiang ChiChing-Shiang Chi
Ching-Shiang Chi
CTChi-Ren Tsai
Chi-Ren Tsai
Yaolun YangYaolun Yang
Yaolun Yang
HLHsiu-Fen Lee.
Hsiu-Fen Lee.
Background: Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is the most common autoimmune encephalitis in children. There is a high probability of recovery if treated promptly. We aimed to analyze the clinical features and long-term outcomes of pediatric patients with anti-NMDA receptor encephalitis. Method: We conducted a retrospective study with definite diagnoses of anti-NMDA receptor encephalitis in 11 children treated in a tertiary referral center between March 2012 and March 2022. Clinical features, ancillary tests, treatment, and outcomes were reviewed. Results: The median age at disease onset was 7.9 years. There were eight females (72.7%) and three males (27.3%). Three (27.3%) patients initially presented with focal and/or generalized seizures and eight (72.7%) with behavioral change. Seven patients (63.6%) revealed normal brain MRI scans. Seven (63.6%) had abnormal EEG results. Ten patients (90.1%) received intravenous immunoglobulin, corticosteroid, and/or plasmapheresis. After a median follow-up duration of 3.5 years, one patient was lost to follow-up at the acute stage, nine (90%) had an mRS ≤ 2, and only one had an mRS of 3. Conclusions: With the early recognition of anti-NMDA receptor encephalitis based on its clinical features and ancillary tests, we were able to treat patients promptly with first-line treatment and achieve favorable neurological outcomes.

15 June 2024 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Open access
Yaolun YangYaolun Yang
Yaolun Yang
HLHsiu-Fen Lee.
Hsiu-Fen Lee.
Ching-Shiang ChiChing-Shiang Chi
Ching-Shiang Chi
CTChi-Ren Tsai
Chi-Ren Tsai
PWPei Yu Wu
Pei Yu Wu
SLShu-Ning Liu
Shu-Ning Liu
Objective: To analyze cerebellar atrophy in genetic epileptic encephalopathies (EEs). Methods: This research included a retrospective cohort study conducted from January 2016 to December 2023 and a systematic review on cerebellar atrophy in genetic EEs. Pediatric individuals who were diagnosed with EEs based on electroclinical features, carried causative gene variants, and exhibited cerebellar atrophy were recruited. Electroclinical features, neuroimaging findings, and causative variants of eligible individuals were analyzed. Results: The cohort study showed 10 of 67 pediatric individuals (10/67; 15 %) who were diagnosed with genetic EEs had cerebellar atrophy; and 6 of the 10 individuals (6/10; 60 %) exhibited cerebellar signs. Diagnostic delay between the detection of cerebellar atrophy and the identification of genetic diagnosis existed in 6 individuals (6/10; 60 %) and the median duration was 4.4 years. A total of 32 genes, including 31 genes from the literature review and a newly identified SCN2A gene in this cohort, were reported associated with cerebellar atrophy in genetic EEs. Twenty-six genes (26/32; 81 %) accounted for cerebellar atrophy associated with other brain anomalies and 6 genes (6/32; 19 %) caused isolated cerebellar atrophy. Twenty-five genes (25/32; 78 %) showed late-onset cerebellar atrophy identified after the age of 1 year old. Conclusion: Cerebellar atrophy is not uncommon in genetic EEs and may serve as an indicator for molecular diagnosis in clinical practice. To shorten the diagnostic delay, follow-up neuroimaging study is crucial because of high rate of clinico-radiological dissociation and late-onset cerebellar atrophy in this patient group.

1 August 2025 in Neurology Genetics
Verified
Journal Article
Open access
Yaolun YangYaolun Yang
Yaolun Yang
HLHsiu-Fen Lee.
Hsiu-Fen Lee.
Ching-Shiang ChiChing-Shiang Chi
Ching-Shiang Chi
CTChi-Ren Tsai
Chi-Ren Tsai
SLShu-Ning Liu
Shu-Ning Liu
PWPei Yu Wu
Pei Yu Wu
The aim of this report was to describe the phenotypic and genotypic spectrum of WDR73-related Galloway-Mowat syndrome (GAMOS). This study comprises a case series conducted from January 2016 to October 2024, along with a systematic review of WDR73-related GAMOS. Analysis was performed on demographic data, clinical features, neuroimaging findings, neurodevelopmental outcomes, and WDR73 gene variants of eligible individuals. We studied 64 individuals, including 4 from this case series and 60 from previous literature. The median reported age at disease onset ranged from 2.5 to 6 months. The most prevalent neurologic feature was microcephaly (55/64; 85.9%), followed by cerebellar atrophy (29/34; 85.3%), ocular abnormalities (54/64; 84.4%), axial hypotonia (52/64; 81.3%), and movement disorders (40/64; 62.5%). Proteinuria (37/64; 57.8%) was the leading extraneurologic feature while hiatal hernia (2/64; 3.1%) was the least observed classic feature. All individuals exhibited psychomotor impairment. A total of 18 WDR73 variants were identified, including 4 novel variants from this case series: c.21G > A (p.Trp7Ter), c.76G > A (p.Ala26Thr), c.214A > G (p.Arg72Gly), and c.884-171_c.*591del. Homozygous WDR73 variants were predominant (61/64; 95.3%) while 3 individuals carried compound heterozygous WDR73 variants. WDR73-related GAMOS is an autosomal recessive, infantile-onset neurodevelopmental disorder with multisystem involvement. Recognizing its clinical manifestations prior to genetic testing may help mitigate reproductive risks and facilitate comprehensive, individualized health care.